Abstracts tagged "Health Services Research"

Abstract Number: 1081 • ACR Convergence 2021
Improving Rheumatology Resource Utilization and Access to Specialty Care for Patients with Early Inflammatory Arthritis Through Enhanced Triage
Kristina Roche¹, John Hanly¹, Jennifer MacKinnon², Susan Parlee², Trudy Taylor¹, Volodko Bakowsky¹, Cheri Gunn², Nikolas Harris³ and Janet Roberts⁴, ¹Dalhousie University, Halifax, NS, Canada, ²Nova Scotia Health Authority, Halifax, NS, Canada, ³The Arthritis Society, Halifax, NS, Canada, ⁴Dalhousie University, Halifac, NS, Canada
Background/Purpose: In many health care jurisdictions the demand for rheumatology consultation exceeds the capacity to provide timely access for all referrals. This has highlighted the…
Abstract Number: 0600 • ACR Convergence 2021
A Cohort Study of Retention in Ambulatory Lupus Care Among Medicare Patients with SLE-related Hospitalizations
Maria Schletzbaum¹, Carlos Torres², Amy Kind², Andrea Gilmore Bykovskyi³, Ann Sheehy² and Christie Bartels², ¹University of Wisconsin School of Medicine and Public Health, Middleton, WI, ²University of Wisconsin School of Medicine and Public Health, Madison, WI, ³University of Wisconsin - Madison School of Nursing, Madison, WI
Background/Purpose: In other conditions that require chronic management, poor retention in ambulatory care is associated with adverse outcomes. We previously identified that living in the…
Abstract Number: 1138 • ACR Convergence 2021
Assessing Trends in Dual Energy X-Ray Absorptiometry (DXA) Utilization Among Medical Providers in the United States
Timothy Edgil¹, Kenneth Saag², Jeffrey Curtis³ and Maria I. Danila², ¹Division of General Internal Medicine, University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The twenty first century has seen falling reimbursement rates for dual energy X-ray absorptiometry (DXA) testing coupled with a rising elderly population in the…
Abstract Number: 0641 • ACR Convergence 2021
Title: EHR-Supported Staff Protocol Improves Smoking Cessation in a Diverse Rheumatology Clinic: Updated Results of Quit Connect Dissemination
Jennifer Brandt¹, Edmond Ramly², Monica Messina³, S Sam Lim⁴ and Christie Bartels³, ¹Emory School of Medicine, Atlanta, GA, ²University of Wisconsin School of Medicine, Madison, WI, ³University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁴Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA
Background/Purpose: Smoking is a risk factor for rheumatologic conditions like lupus and rheumatoid arthritis and predicts worse outcomes. Smoking and rheumatic disease increase risk for…
Abstract Number: 1154 • ACR Convergence 2021
What Do Patients Know About Biosimilars and How Satisfied Are They with the Educational Process? – A Systematic Comparison Between Rheumatologists and Nurse Specialists, Including Effects of Multiswitching
Sabina Gall, Uta Kiltz, Tanja Kobylinski, Ioana Andreica, Kristina Vaupel, Xenofon Baraliakos and Jürgen Braun, Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany
Background/Purpose: The market share of biosimilars (bsDMARDs) is steadily growing, not only in rheumatologic care. Although data on efficacy, efficiency and safety have been generated…
Abstract Number: 0643 • ACR Convergence 2021
Tailored BP Connect Protocol with Implementation Support for Rheumatology Clinic Staff Exceeds Non-tailored Protocol at Improving Primary Care Referrals for Blood Pressure Follow-up
David Gazeley¹, Monica Messina², Edmond Ramly², Ann Rosenthal¹, Laurie Lapp², Laura Stewart³ and Christie Bartels², ¹Medical College of Wisconsin, Milwaukee, WI, ²University of Wisconsin School of Medicine and Public Health, Madison, WI, ³Froedtert & Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Many rheumatic diseases increase risk of cardiovascular disease, yet an important modifiable cardiovascular risk factor, high blood pressure (BP), often remains unaddressed during rheumatology…
Abstract Number: 1272 • ACR Convergence 2021
Characterizing Patient and Physician Perceptions of Systemic Lupus Erythematosus (SLE) Disease Burden Using Traditional Rheumatoid Arthritis Outcomes Measures
Christopher Bell¹, Shirley Huang¹, Meg Wang², Maral DerSarkissian², Mei Sheng Duh², Bhavna Dhillon³, Carlyne Averell¹, Bernie Rubin¹ and Daniel Wallace⁴, ¹GlaxoSmithKline, Research Triangle Park, NC, ²Analysis Group, Boston, MA, ³United Rheumatology, Hauppauge, NY, ⁴Cedars-Sinai, Los Angeles, CA
Background/Purpose: SLE is a chronic, autoimmune disease affecting multiple organ systems, and characterized by fluctuating disease activity. Many SLE disease measures may be impractical for…
Abstract Number: 0644 • ACR Convergence 2021
Follow-up Scheduling Appears Essential for Success of Rheumatology High Blood Pressure Protocol Across Health Systems
Christie Bartels, Bret Hanlon, Monica Messina, Sancia Ferguson and Edmond Ramly, University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: To address high blood pressure (BP), target of two ACR quality measures and the leading modifiable risk factor for cardiovascular disease, we previously developed…
Abstract Number: 1597 • ACR Convergence 2021
Arthritis Patient Perspectives on Virtual Care for People Living with Arthritis During the COVID-19 Pandemic and for the Future
Maya Joshi¹, Anita Chan¹, Adriana Lima², Kelly Lendvoy¹, Eric Sayre² and Cheryl Koehn¹, ¹Arthritis Consumer Experts, Vancouver, BC, Canada, ²Arthritis Research Canada, Richmond, BC, Canada
Background/Purpose: Virtual Care (VC) is the delivery of health care services and information by electronic methods (video, smartphones, email, text) and may support arthritis patients…
Abstract Number: 0666 • ACR Convergence 2021
Process Mapping Gout Hospitalizations: A Deep Dive into an Avoidable Epidemic
Mark Russell¹, Benjamin Ellis², Benjamin Clarke¹, Deepak Nagra¹ and James Galloway³, ¹King's College London, London, United Kingdom, ²Imperial College Healthcare NHS Trust, London, United Kingdom, ³Kings College London, London, United Kingdom
Background/Purpose: Hospital admissions for gout flares have increased dramatically in recent years. Strategies to reduce hospitalizations and improve uptake of urate-lowering therapy (ULT) are needed.…
Abstract Number: 1838 • ACR Convergence 2021
Further Construct Validation of the
Julia Spierings¹, Voon Ong² and Christopher Denton³, ¹University Medical Center Utrecht, Utrecht, Netherlands, ²University College London Medical School Royal Free Campus, London, United Kingdom, ³University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom
Background/Purpose: Evaluation of skin is central in clinical management of systemic sclerosis (SSc). Due to the COVID-19 pandemic remote consultations were widely implemented, which inevitably…
Abstract Number: 0129 • ACR Convergence 2021
Real-World Flare Rates and Progression by Treatment Settings Among the Commercially-Insured Systemic Lupus Erythematosus Population in the U.S
Sandra Sze-jung Wu¹, Allison Perry², Helen Varker², Richard Bizier², Joseph Tkacz² and Robert Ortmann³, ¹AstraZeneca, Wilmington, DE, ²IBM Watson Health, Bethesda, MD, ³AstraZeneca, Greenwood, IN
Background/Purpose: The clinical presentation of systemic lupus erythematosus (SLE) is complicated, as patients cycle through periods of active disease (flares) and remission. To establish the…
Abstract Number: 0767 • ACR Convergence 2021
Medication Use in Pediatric Lupus in the Childhood Arthritis and Rheumatology Research Alliance Registry
Jordan Roberts¹, Laura Berbert¹ and Mary Beth Son², ¹Boston Children's Hospital, Boston, MA, ²Boston Children's Hospital, Brookline, MA
Background/Purpose: Black and Hispanic children with pediatric lupus (pSLE) have higher morbidity and mortality, but the extent to which differences in outcomes may be related…
Abstract Number: 1896 • ACR Convergence 2021
Initial Results from the Implementation of a National Hydroxychloroquine Safe Prescribing Dashboard Within the Veterans Health Administration
Anna Montgomery¹, Gary Tarasovsky², Iziegbe Ehiorobo³, Mary Whooley², Jennifer Barton⁴, Khushboo Sheth⁵, Kimberly Reiter⁶, Meredith Keller⁷, Lorinda Chung⁸, Lori Bennett⁹, Jo Dana², Elizabeth Wahl¹⁰ and Gabriela Schmajuk³, ¹Department of Veterans Affairs, Tiburon, CA, ²San Francisco VA Healthcare System, San Francisco, CA, ³University of California San Francisco, San Francisco, CA, ⁴Portland VA Healthcare System, Portland, OR, ⁵Stanford University/VA Palo Alto, Atherton, CA, ⁶Raymond G Murphy VA Medical Center, Albuquerque, NM, ⁷New Mexico VA Health Care System, Albuquerque, NM, ⁸Stanford University, Palo Alto, CA, ⁹Charleston VAHCS, Charleston, SC, ¹⁰VA Puget Sound Health Care System, Seattle, WA
Background/Purpose: Hydroxychloroquine (HCQ) is a commonly used medication for patients with lupus erythematosus, rheumatoid arthritis, and other autoimmune conditions. However, HCQ daily doses of ≥…
Abstract Number: 0130 • ACR Convergence 2021
Clinical and Economic Characterization of Systemic Lupus Erythematosus Patients: Real World Observation Across Disease Severity and Payer Channels in the U.S
Joseph Tkacz¹, Allison Perry¹, Helen Varker¹, Richard Bizier¹, Robert Ortmann² and Sandra Sze-jung Wu³, ¹IBM Watson Health, Bethesda, MD, ²AstraZeneca, Greenwood, IN, ³AstraZeneca, Wilmington, DE
Background/Purpose: Current literature characterizing the economic and clinical burden of systemic lupus erythematosus (SLE) is outdated and often does not consider SLE disease severity, which…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].